Oculogenex

Using gene therapy to improve vision for our generation

Our novel investigational gene therapy is being developed to stop the degeneration of central vision in patients with macular degeneration and dramatically improve their quality of life.

Our Story

Oculogenex was founded by an ophthalmologist committed to developing better treatment options for her patients with blinding retinal diseases. Not satisfied with the fact that so many patients with dry macular degeneration are losing vision without any treatment options, she began the journey to find hope and a solution for her patients. She developed a gene therapy to treat dry macular degeneration with promise for other degenerative retinal diseases.

News

SpaceX 30 Launch

Watch history in the making as NASA’s SpaceX 30 commercial resupply mission launches Oculogenex’ ophthalmic gene therapy to ISS-NL. This will be the first gene therapy and investigational ophthalmic therapy sent to space. Status is Go For Launch on 3/21/2024 at 4:55 PM EST.

Click Here for the Live Feed

Gene Therapy in Space

Oculogenex’s CEO discusses the company’s gene therapy in a feature on Eyewire TV.

Click Here To Learn More

LABEST

Oculogenex has been selected as one of LA’s Best biotech companies and will be showcased at the LA BEST Summit in 2021. Please catch this amazing virtual event.

More Info

MassChallenge

Oculogenex has been invited to participate in Round 2 of the MassChallenge Boston competition. MassChallenge is a non-profit organization dedicated to supporting innovation and entrepreneurship through collaboration and development.

SBIR Grant Awarded to Oculogenex

Oculogenex has been awarded an SBIR Phase I Grant by the National Science Foundation to study the use of our novel therapy for treatment of macular degeneration.

2/6/2021 - Oculogenex Wins First Prize in the Winning Pitch Challenge!

Contact: info@oculogenex.com